TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39705739

Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation during general anesthesia with low end-tidal CO2 (etCO2)
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1843
Study: 39705855

Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Troponin (3rd-hour)
Number of subjects: 174
Study: 39706105

Group type: EXPERIMENTAL
Intervention: Goal attainment theory-based intervention
Number of subjects: 157

Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 157
Study: 39706212

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 2×10^6 allogeneic umbilical cord-derived mesenchymal stromal cells
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 39706209

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg given intravenously at weeks 0, 4, and 8 (induction)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg given subcutaneously every 4 weeks (maintenance)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg given subcutaneously every 8 weeks (maintenance)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo (induction)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 701
Study: 39706330

Group type: EXPERIMENTAL
Intervention: Enhanced Adolescent Community Reinforcement Approach (E-ACRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assertive Community Support (ACS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-ACRA
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACS
Number of subjects: 0
Study: 39706335

Group type: EXPERIMENTAL
Intervention: avelumab + axitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: sunitinib
Number of subjects: 0
Study: 39706483

Group type: EXPERIMENTAL
Intervention: tPBM
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 48
Study: 39706632

Group type: EXPERIMENTAL
Intervention: NG101 (45 mg intrathecal injections, 6 doses every 5 days over 4 weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: NG101
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 39706650

Group type: EXPERIMENTAL
Intervention: Community Mobilisation and Incentivisation
Number of subjects: 21638

Group type: COMPARATOR
Intervention: Community Mobilisation
Number of subjects: 21638
Study: 39706666

Group type: EXPERIMENTAL
Intervention: TdaP vaccine
Number of subjects: 181

Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 181
Study: 39706691

Group type: EXPERIMENTAL
Intervention: Clear aligner (CA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Removable inclined plane (RIP)
Number of subjects: 24
Study: 39706761

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF) fixed dosing (45/200 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Population PK modeling
Number of subjects: 22
Study: 39706803

Group type: EXPERIMENTAL
Intervention: STRIDE (group psychosocial telehealth intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medication monitoring (control group)
Number of subjects: 100
Study: 39706874

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 640

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 640
Study: 39706981

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 101
Study: 39707032

Group type: EXPERIMENTAL
Intervention: AIIR (grades 1-5)
Number of subjects: 62

Group type: COMPARATOR
Intervention: AIIR (grades 3 and 5)
Number of subjects: 62

Group type: COMPARATOR
Intervention: SDCT (Karl 3D-5)
Number of subjects: 62

Group type: COMPARATOR
Intervention: LDCT (Karl 3D-5 and AIIR-3 and 5)
Number of subjects: 62
Study: 39707042

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 3481

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 3481

Group type: EXPERIMENTAL
Intervention: Tofacitinib (3rd-line)
Number of subjects: 3481
Study: 39707077

Group type: EXPERIMENTAL
Intervention: Risankizumab 1800 mg intravenous infusion once every 4 weeks for four doses
Number of subjects: 20
Study: 39707126

Group type: EXPERIMENTAL
Intervention: Dual-phase cone-beam CT (CBCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pre-treatment contrast-enhanced CT (CECT)
Number of subjects: 30
Study: 39707137

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT), administered once every other day for 30 min per session, totaling 14 sessions over 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (HCs), no SMT treatment
Number of subjects: 31
Study: 39707138

Group type: EXPERIMENTAL
Intervention: Juan Bi Pill (JBP) combined with Methotrexate (MTX, 10 mg per week)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo combined with Methotrexate (MTX, 10 mg per week)
Number of subjects: 115
Study: 39707158

Group type: COMPARATOR
Intervention: Dulce Digital (DD)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (DD-Me-Auto)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Dulce Digital-Me (DD-Me-Tel)
Number of subjects: 310
Study: 39707209

Group type: EXPERIMENTAL
Intervention: Liberal oxygen therapy (target SpO2 of ≥ 96%)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conservative oxygen therapy (target SpO2 of 88-92%)
Number of subjects: 106
Study: 39707229

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ITT analysis of brigatinib
Number of subjects: 0
Study: 39707239

Group type: EXPERIMENTAL
Intervention: Drug tapering and treatment for underlying psychiatric disorders
Number of subjects: 405
Study: 39707275

Group type: EXPERIMENTAL
Intervention: Benign hysterectomy
Number of subjects: 440
Study: 39707277

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined diet and exercise intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 39707287

Group type: EXPERIMENTAL
Intervention: Active Break intervention (AB-group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-administered care recommendations (C-group)
Number of subjects: 50
Study: 39707376

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 190
Study: 39707385

Group type: EXPERIMENTAL
Intervention: Wrist vibratory reminders during a six-week home-based intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Wrist vibratory reminders during a six-week home-based intervention (for participants with sufficient sensor data)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Initial impairment level
Number of subjects: 42
Study: 39707407

Group type: EXPERIMENTAL
Intervention: Perioperative methadone (0.10 mg/kg, administered intravenously at anesthesia induction)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Perioperative methadone
Number of subjects: 130
Study: 39707490

Group type: EXPERIMENTAL
Intervention: ESBL-positive-at-admission (PA-ESBL) patients
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: ESBL-negative-at-admission (NA-ESBL) patients
Number of subjects: 3703

Group type: COMPARATOR
Intervention: Patients receiving antibiotics
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: Endogenous infections
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: Direct between-patients transmission clusters
Number of subjects: 3703
Study: 39707531

Group type: EXPERIMENTAL
Intervention: Critically short telomeres (%CST)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Critically short telomeres (%CST) in APOE4 carriers
Number of subjects: 129
Study: 39707544

Group type: EXPERIMENTAL
Intervention: Males who showed interest in the trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Males attending an in-person information session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Females attending an in-person information session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males and females who demonstrated initial interest
Number of subjects: 0
Study: 39707595

Group type: EXPERIMENTAL
Intervention: Palbociclib + ET (PALBO)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Ribociclib + ET (RIBO)
Number of subjects: 623
Study: 39707865

Group type: EXPERIMENTAL
Intervention: 100% fish oil lipid emulsion (FOLE) 1 g/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100% soybean oil lipid emulsion (SOLE) 1.9 g/kg
Number of subjects: 0
Study: 39708027

Group type: EXPERIMENTAL
Intervention: LVEDD <55 mm
Number of subjects: 1921
Study: 39708035

Group type: EXPERIMENTAL
Intervention: HPSD 70 W/9-10 s
Number of subjects: 304

Group type: COMPARATOR
Intervention: CPD 25-40 W
Number of subjects: 304
Study: 39708049

Group type: EXPERIMENTAL
Intervention: Popliteal vein functional diameter measurement before and after compression with thigh inflatable cuff
Number of subjects: 173
Study: 39708052

Group type: EXPERIMENTAL
Intervention: Toxin withdrawal in mice for 1 or 2 weeks
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prolonged abstinence in patients with alcohol-related cirrhosis
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Persistent hepatic proinflammatory environment in regressive mice
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher CRP, IL-6, IgA, and IgG levels in abstinent patients
Number of subjects: 128
Study: 39708086

Group type: EXPERIMENTAL
Intervention: 2G oral semaglutide (9 mg)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 2G oral semaglutide (4 mg)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 2G oral semaglutide (1.5 mg)
Number of subjects: 222

Group type: COMPARATOR
Intervention: 2G oral semaglutide
Number of subjects: 222
Study: 39708224

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing from a Registered Dietitian (RDMI) during a 6-month intensive Food is Medicine (FIM) intervention
Number of subjects: 85
Study: 39708245

Group type: EXPERIMENTAL
Intervention: Very-high-power short-duration (vHPSD) radiofrequency ablation (90 W, 4 s)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional treatment (25-40 W applications, unlimited duration)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Very-high-power short-duration (vHPSD) radiofrequency ablation
Number of subjects: 2
Study: 39708253

Group type: EXPERIMENTAL
Intervention: Partial nephrectomy (PN)
Number of subjects: 20523

Group type: EXPERIMENTAL
Intervention: Local tumor destruction (LTD)
Number of subjects: 20523

Group type: COMPARATOR
Intervention: Synchronous BRCC
Number of subjects: 20523

Group type: COMPARATOR
Intervention: Metachronous BRCC
Number of subjects: 20523

Group type: COMPARATOR
Intervention: Radical nephrectomy
Number of subjects: 20523
Study: 39708367

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 120
Study: 39708369

Group type: EXPERIMENTAL
Intervention: Topical ruxolitinib 1.5% cream applied twice daily for 16 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Topical ruxolitinib treatment
Number of subjects: 6
Study: 39708537

Group type: EXPERIMENTAL
Intervention: Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) with doses of 7.5-12.5-35-70 mg/m2 heated at 39±1 °C
Number of subjects: 15
Study: 39708826

Group type: EXPERIMENTAL
Intervention: LVA therapy (2 g amoxicillin: 1 g twice a day)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: HVA therapy (3 g amoxicillin: 1 g three times a day)
Number of subjects: 504

Group type: COMPARATOR
Intervention: LVA therapy
Number of subjects: 504

Group type: COMPARATOR
Intervention: HVA therapy
Number of subjects: 504
Study: 39708824

Group type: EXPERIMENTAL
Intervention: MMV533
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MMV533 (fasted)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MMV533 (fed)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: MMV533 (after high-fat meal)
Number of subjects: 69
Study: 39709140

Group type: EXPERIMENTAL
Intervention: HEC88473 (30.6 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HEC88473 (68.0 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HEC88473
Number of subjects: 60
Study: 39709189

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block and popliteal plexus block
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous femoral nerve block alone
Number of subjects: 66
Study: 39709368

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team assessment and individualized treatment (MDT)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 39709372

Group type: EXPERIMENTAL
Intervention: PULSAR with HyperArc© software, 11 Gray fraction of radiation every two weeks for a total of five fractions (total dose of 55 Gy)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PULSAR with HyperArc© software
Number of subjects: 43
Study: 39709402

Group type: EXPERIMENTAL
Intervention: L-PRF loaded with Metronidazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: L-PRF alone
Number of subjects: 24
Study: 39709419

Group type: EXPERIMENTAL
Intervention: Mild sedation and analgesia
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 96
Study: 39709421

Group type: EXPERIMENTAL
Intervention: Grasp neuroprosthesis (GNP) with self-triggering control modalities (EMG, IMU, foot switches, voice commands)
Number of subjects: 22

Group type: COMPARATOR
Intervention: EMG control modality
Number of subjects: 22

Group type: COMPARATOR
Intervention: IMU control modality
Number of subjects: 22

Group type: COMPARATOR
Intervention: Voice control
Number of subjects: 22

Group type: COMPARATOR
Intervention: Head lateral inclination
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GNP responsiveness
Number of subjects: 22
Study: 39709459

Group type: EXPERIMENTAL
Intervention: PTSD Coach mobile app
Number of subjects: 39

Group type: COMPARATOR
Intervention: Attention-control tasks
Number of subjects: 39
Study: 39709458

Group type: EXPERIMENTAL
Intervention: Supportive Parents-Coping Kids (SPARCK) parent training intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive Parents-Coping Kids (SPARCK)
Number of subjects: 0
Study: 39709468

Group type: EXPERIMENTAL
Intervention: AB-free kava, 3 times per day for 4 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo, 3 times per day for 4 weeks
Number of subjects: 76
Study: 39709493

Group type: EXPERIMENTAL
Intervention: Optimized restrictive fluid strategy (reducing fluid intake as much as possible in terms of maintenance fluids and fluids for drug dilution during the first 7 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard fluid strategy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Optimized restrictive fluid strategy
Number of subjects: 50
Study: 39709751

Group type: COMPARATOR
Intervention: Magnitude of variability analysis using principal component scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structure of variability analysis using principal component scores
Number of subjects: 0
Study: 39709786

Group type: EXPERIMENTAL
Intervention: Nurse practitioner-led collaborative health care model (12-week program)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing guidance (Control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nurse practitioner-led collaborative health care model
Number of subjects: 100
Study: 39709979

Group type: EXPERIMENTAL
Intervention: Transfluthrin-based spatial repellent
Number of subjects: 3072

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3072
Study: 39710167

Group type: EXPERIMENTAL
Intervention: ceftazidime-avibactam + metronidazole for 5-14 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ceftazidime-avibactam + metronidazole
Number of subjects: 60
Study: 39710171

Group type: EXPERIMENTAL
Intervention: synbiotic mix (COMP group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: synbiotic mix enriched with pigmented corn extract (EXP group)
Number of subjects: 41
Study: 39710337

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) intervention promoting appropriate gestational weight gain (GWG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 39710352

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Other calcium-modifying techniques (modified or super high-pressure balloon and atheroablative devices)
Number of subjects: 666
Study: 39710508

Group type: EXPERIMENTAL
Intervention: Dostarlimab monotherapy (Arm A)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Dostarlimab + bevacizumab (Arm B)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (Arm C)
Number of subjects: 198
Study: 39710693

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (20 mg/day on days 1-5, 10 mg/day on days 6-10)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard-dose dexamethasone (6 mg/day, days 1-10)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard-dose dexamethasone
Number of subjects: 234
Study: 39710697

Group type: EXPERIMENTAL
Intervention: ICG-HSA complex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-recommended ICG administration scheme
Number of subjects: 0
Study: 39710733

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 123
Study: 39711127

Group type: EXPERIMENTAL
Intervention: 6-4-0 (liberal group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 6-4-2 (standard group)
Number of subjects: 200
Study: 39711191

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39711194

Group type: EXPERIMENTAL
Intervention: Propolis-based protocol for oral health in palliative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39711285

Group type: EXPERIMENTAL
Intervention: Early PBO (< 46 years)
Number of subjects: 231
Study: 39711425

Group type: EXPERIMENTAL
Intervention: Vancomycin administration with negative pressure wound therapy (NPWT)
Number of subjects: 10
Study: 39711430

Group type: EXPERIMENTAL
Intervention: Anlotinib plus PD-1 inhibitor
Number of subjects: 29
Study: 39711557

Group type: EXPERIMENTAL
Intervention: Medications for opioid use disorder (MOUD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Barriers to treatment initiation and retention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Organizational characteristics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Community characteristics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Policy changes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Community-level efforts
Number of subjects: 60
Study: 39711560

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention for acute myocardial infarction diagnosis and treatment
Number of subjects: 0
Study: 39711702

Group type: EXPERIMENTAL
Intervention: Citalopram with grief-informed clinical management
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Citalopram with prolonged grief disorder therapy (PGDT)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Pill placebo with PGDT
Number of subjects: 333

Group type: COMPARATOR
Intervention: Pill placebo with clinical management
Number of subjects: 333
Study: 39711790

Group type: EXPERIMENTAL
Intervention: Mechanical rotation chair (MRC) diagnostics
Number of subjects: 215

Group type: COMPARATOR
Intervention: Traditional manual BPPV diagnostics (MD)
Number of subjects: 215
Study: 39711792

Group type: EXPERIMENTAL
Intervention: Intra-arterial cocktail therapy with argatroban, dexamethasone, and edaravone administered for 30 minutes into the culprit artery after sufficient recanalization.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (retrospective data of patients who met inclusion/exclusion criteria).
Number of subjects: 30
Study: 39712455

Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with fulvestrant
Number of subjects: 46
Study: 39712511

Group type: EXPERIMENTAL
Intervention: Dyadic Mindfulness Self-Compassion intervention (six weekly sessions)
Number of subjects: 0
Study: 39713041

Group type: EXPERIMENTAL
Intervention: ANG1005 (600 mg/m2)
Number of subjects: 73
Study: 39713088

Group type: EXPERIMENTAL
Intervention: Telehealth behavioral weight loss program
Number of subjects: 21
Study: 39713266

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 39713278

Group type: EXPERIMENTAL
Intervention: lehfilcon A (TOTAL30 for Astigmatism) contact lenses worn from 8:00 AM until 12:00 AM each day for 1 month
Number of subjects: 47
Study: 39713795

Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention to improve adherence to PPI; 122 out of 178 non-adherent patients received the intervention.
Number of subjects: 351
Study: 39713935

Group type: EXPERIMENTAL
Intervention: Domagrozumab (an antibody-targeting myostatin)
Number of subjects: 0
Study: 39714033

Group type: EXPERIMENTAL
Intervention: Telehealth physical activity counseling intervention
Number of subjects: 24